DE69822234D1 - Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion - Google Patents

Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion

Info

Publication number
DE69822234D1
DE69822234D1 DE69822234T DE69822234T DE69822234D1 DE 69822234 D1 DE69822234 D1 DE 69822234D1 DE 69822234 T DE69822234 T DE 69822234T DE 69822234 T DE69822234 T DE 69822234T DE 69822234 D1 DE69822234 D1 DE 69822234D1
Authority
DE
Germany
Prior art keywords
olanzapine
neuroprotection
medicament
manufacture
neuro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69822234T
Other languages
English (en)
Other versions
DE69822234T2 (de
Inventor
Franklin Porter Bymaster
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69822234D1 publication Critical patent/DE69822234D1/de
Application granted granted Critical
Publication of DE69822234T2 publication Critical patent/DE69822234T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69822234T 1997-04-15 1998-04-09 Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion Expired - Fee Related DE69822234T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4309497P 1997-04-15 1997-04-15
US43094 1997-04-15

Publications (2)

Publication Number Publication Date
DE69822234D1 true DE69822234D1 (de) 2004-04-08
DE69822234T2 DE69822234T2 (de) 2005-02-24

Family

ID=21925472

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69822234T Expired - Fee Related DE69822234T2 (de) 1997-04-15 1998-04-09 Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
DE69804034T Expired - Fee Related DE69804034T2 (de) 1997-04-15 1998-04-09 Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69804034T Expired - Fee Related DE69804034T2 (de) 1997-04-15 1998-04-09 Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion

Country Status (8)

Country Link
EP (1) EP0872238B1 (de)
AT (2) ATE213945T1 (de)
AU (1) AU6955998A (de)
DE (2) DE69822234T2 (de)
DK (1) DK0872238T3 (de)
ES (2) ES2215851T3 (de)
PT (2) PT872238E (de)
WO (1) WO1998046596A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5744470A (en) * 1996-03-11 1998-04-28 Eli Lilly And Company Method for treating insomnia
US5744469A (en) * 1996-11-26 1998-04-28 Eli Lilly And Company Method for treating dermatitis

Also Published As

Publication number Publication date
ATE213945T1 (de) 2002-03-15
WO1998046596A1 (en) 1998-10-22
DE69804034D1 (de) 2002-04-11
EP0872238B1 (de) 2002-03-06
AU6955998A (en) 1998-11-11
ATE260662T1 (de) 2004-03-15
ES2215851T3 (es) 2004-10-16
EP0872238A3 (de) 1998-10-28
EP0872238A2 (de) 1998-10-21
ES2173550T3 (es) 2002-10-16
DK0872238T3 (da) 2002-06-24
DE69804034T2 (de) 2002-10-17
PT872238E (pt) 2002-07-31
DE69822234T2 (de) 2005-02-24
PT1155696E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
HK1042825A1 (zh) 治療氣道疾病的化合物和方法以及氣道藥物的給藥方法
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE59611383D1 (de) Darreichungsform zur applikation von pharmazeutischen wirkstoffen und hilfsstoffen und verfahren zur herstellung derselben
NO944339D0 (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
DE69804034T2 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee